CJUOpen Access

Canadian Journal of Urology

ISSN:1195-9479(print)
ISSN:1488-5581(online)
Publication Frequency:Bi-monthly

  • Online
    Articles

    586

  • on board
    editors

    41

Special Issues

About the Journal

The Canadian Journal of Urology (CJU) is a peer-reviewed indexed journal that is published and included in the Journal Citation Reports/Science Edition. The journal has steadily gained recognition in the medical community within Canada and abroad, and continues to successfully disseminate the latest scientific knowledge in the field of urology. We welcome the urological medical community to submit original research articles, review articles, practice updates and case reports. All submissions are peer-reviewed by the CJU's peer review board hand-picked by our editorial board, under the leadership of our Editor-in-Chief. The Canadian Journal of Urology has been published continuously since 1994. In November 2000, the journal was accepted for indexation in Index Medicus and MEDLINE. All issues from its inception to the present are archived and accessible at PubMed Central, the US National Library of Medicine's database of journals.

Indexing and Abstracting

Science Citation Index Expanded (SCIE): 2023 Impact Factor 1.2; Scopus: Citescore 1.9 (2023), SNIP 0.426 (2023); MEDLINE/PubMed; EMBASE

Effective 2025, the Canadian Journal of Urology (CJU) will be published by Tech Science Press (TSP). This transition is designed to enhance the journal’s academic impact and global visibility while ensuring an improved publishing experience for researchers. The journal's aims, scope, and formatting guidelines will remain unchanged. The journal's Editor-in-Chief, Prof. Leonard Gomella, and the editorial board will continue to lead the journal toward an even more successful future.
We appreciate the ongoing support of our authors, reviewers, and readers as we embark on this exciting new chapter.

  • Open Access

    EDITORIAL

    What Makes a Good Surgeon? What I Learned Watching Hardy Hendren

    Canadian Journal of Urology, Vol.32, No.2, pp. 71-72, 2025, DOI:10.32604/cju.2025.066690 - 30 April 2025
    Abstract This article has no abstract. More >

  • Open Access

    LEGENDS IN UROLOGY

    Legends in Urology: Reflections on a Career in Academic Urology

    Canadian Journal of Urology, Vol.32, No.2, pp. 73-80, 2025, DOI:10.32604/cju.2025.064714 - 30 April 2025
    Abstract This article has no abstract. More >

  • Open Access

    ARTICLE

    Emergency room management of urolithiasis: a sex-based comparison

    Canadian Journal of Urology, Vol.32, No.2, pp. 81-88, 2025, DOI:10.32604/cju.2025.063415 - 30 April 2025
    Abstract Introduction: Existing literature has highlighted disparities in acute pain management across racial and sex groups in both emergency department and pre-hospital settings. This study aimed to evaluate prescribing patterns among physicians and advanced practice providers for patients with upper tract urolithiasis in an academic emergency department. Materials and Methods: Retrospective chart review of patients diagnosed with upper tract urolithiasis was performed to evaluate age, sex, race, ethnicity, stone size and location, presence of hydronephrosis, admission status, history of prior nephrolithiasis, medications administered in the emergency department (ED), requests for urology consult or referral, and discharge medications. More >

  • Open Access

    ARTICLE

    The cost and guideline adherence of direct-to-consumer telemedicine companies offering gender-affirming hormone therapy

    Canadian Journal of Urology, Vol.32, No.2, pp. 89-94, 2025, DOI:10.32604/cju.2025.065004 - 30 April 2025
    Abstract Introduction: Direct-to-consumer (DTC) telemedicine has emerged as an option for transgender patients seeking gender affirming hormone therapy (GAHT). We aimed to characterize the healthcare services provided by DTC telemedicine companies offering GAHT and to compare their costs to a tertiary care center. Methods: We identified DTC telemedicine platforms offering GAHT via internet searches and extracted information from their websites related to evaluation, treatment, monitoring, and cost. Cost of the DTC GAHT was compared to cost for comparable services at a tertiary care center. Results: Six DTC companies were identified. All platforms utilized an informed consent model… More >

  • Open Access

    ARTICLE

    The intersection of histologies: navigating the complexity of a renal collision tumor

    Canadian Journal of Urology, Vol.32, No.2, pp. 95-99, 2025, DOI:10.32604/cju.2025.065002 - 30 April 2025
    Abstract Renal cell carcinoma is a heterogeneous group of renal tumors characterized by several histological subtypes. Herein, we discuss an unusual case of a 55-year-old male who presented as a consultation to our urology clinic with an incidentally found renal mass. After shared decision making patient proceeded with a Robotic Assisted Laparoscopy (RAL) left sided partial nephrectomy. Final pathology confirmed the presence of high nuclear grade mixed clear cell and papillary renal cell carcinoma (RCC) of the left kidney (pT3aN0M0). This case elucidates a very rare incidence of a patient seen to have a collision tumor, More >

  • Open Access

    ARTICLE

    Differences at diagnosis between long-term survivors and not long-term survivors in metastatic renal cell carcinoma initially treated with TKI

    Canadian Journal of Urology, Vol.32, No.2, pp. 101-109, 2025, DOI:10.32604/cju.2025.063073 - 30 April 2025
    Abstract Introduction: In recent years, significant advancements in the treatment of metastatic renal cell carcinoma (mRCC) have notably extended overall survival (OS) times, particularly with the introduction of tyrosine kinase inhibitors (TKIs) and combination immunotherapy. However, survival outcomes in mRCC remain highly variable. Materials and Methods: This study retrospectively analyzed clinical and demographic factors at diagnosis in patients treated for mRCC to identify predictors of long-term survival (defined as OS ≥ 48 months). Patients were categorized into long-term survivors (LTS) and non-long-term survivors (nLTS). Results: The analysis revealed that factors such as better Karnofsky Performance Status (KPS), More >

  • Open Access

    ARTICLE

    Comparison of clinical effectiveness and safety of 272 µm and 365 µm holmium lasers in retrograde intrarenal surgery

    Canadian Journal of Urology, Vol.32, No.2, pp. 111-118, 2025, DOI:10.32604/cju.2025.063970 - 30 April 2025
    Abstract Introduction: Surgeons typically prefer 270 µm and 272 µm laser probes in retrograde intrarenal surgery (RIRS) due to the reduced deflection capacity of flexible ureterorenoscopes when using larger probe diameters. This study aims to investigate the effects of 272 and 365 µm holmium laser probes on operative time, clinical efficacy, and complication rates in RIRS. Materials and Methods: A total of 285 patients with proximal ureteral or kidney stones who met the inclusion criteria were enrolled in the study. Patients were divided into two groups based on laser probe thickness: 272 µm and 365 µm. Stone-free… More >

  • Open Access

    ARTICLE

    Comparing functional outcomes of glansectomy with or without glans reconstruction

    Canadian Journal of Urology, Vol.32, No.2, pp. 119-127, 2025, DOI:10.32604/cju.2025.063821 - 30 April 2025
    Abstract Introduction: We aimed to compare the oncological and functional outcomes of glansectomy and split-thickness skin graft reconstruction (GR) with those of glansectomy alone (GA) and penile amputation (PA). Materials and Methods: This retrospective study included patients with penile carcinoma or penile intraepithelial neoplasia diagnosed between 2017 and 2022. Surgical outcomes, complications, and oncological outcomes were assessed through a chart review, and functional outcomes were assessed using a questionnaire administered to patients who underwent GR (group A), GA (group B), or PA (group C). Results: Six, eight, and seven patients were enrolled in groups A, B, and… More >

Copyright © 2025 The Author(s). Published by Tech Science Press.

Share Link